Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer

Morten Ladekarl^*, Louise Skau Rasmussen, Jakob Kirkegård, Inna Chen, Per Pfeiffer, Britta Weber, Halla Skuladottir, Kell Østerlind, Jim Stenfatt Larsen, Frank Viborg Mortensen, Henriette Engberg, Henrik Møller, Claus Wilki Fristrup

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

4 Citations (Scopus)

29 Downloads (Pure)

1 results
- Title
- Start date(descending)

Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer
Ladekarl, M. (Creator), Rasmussen, L. S. (Creator), Kirkegård, J. (Creator), Chen, I. (Creator), Pfeiffer, P. (Creator), Weber, B. (Creator), Skuladottir, H. (Creator), Østerlind, K. (Creator), Larsen, J. S. (Creator), Mortensen, F. V. (Creator), Engberg, H. (Creator), Møller, H. (Creator) & Fristrup, C. W. (Creator), Taylor & Francis, 2021
DOI: 10.6084/m9.figshare.17150821.v1, https://tandf.figshare.com/articles/journal_contribution/Disparity_in_use_of_modern_combination_chemotherapy_associated_with_facility_type_influences_survival_of_2655_patients_with_advanced_pancreatic_cancer/17150821/1
Dataset

Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer

Datasets

Search results

Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer